Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Liabilities and Shareholders Equity: 2015-2024

Historic Liabilities and Shareholders Equity for Wave Life Sciences (WVE) over the last 10 years, with Dec 2024 value amounting to $352.2 million.

  • Wave Life Sciences' Liabilities and Shareholders Equity fell 32.67% to $241.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 5.27%. This contributed to the annual value of $352.2 million for FY2024, which is 28.10% up from last year.
  • Latest data reveals that Wave Life Sciences reported Liabilities and Shareholders Equity of $352.2 million as of FY2024, which was up 28.10% from $274.9 million recorded in FY2023.
  • Wave Life Sciences' 5-year Liabilities and Shareholders Equity high stood at $352.2 million for FY2024, and its period low was $146.4 million during FY2022.
  • Over the past 3 years, Wave Life Sciences' median Liabilities and Shareholders Equity value was $274.9 million (recorded in 2023), while the average stood at $257.8 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first dropped by 29.28% in 2022, then surged by 87.82% in 2023.
  • Yearly analysis of 5 years shows Wave Life Sciences' Liabilities and Shareholders Equity stood at $279.2 million in 2020, then decreased by 25.87% to $207.0 million in 2021, then declined by 29.28% to $146.4 million in 2022, then soared by 87.82% to $274.9 million in 2023, then rose by 28.10% to $352.2 million in 2024.